Robustness of FTIR-Based Ultrarapid COVID-19 Diagnosis Using PLS-DA

The World Health Organization (WHO) declared the Omicron variant (B.1.1.529) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for the Coronavirus disease 2019 (COVID-19) pandemic, as a variant of concern on 26 November 2021. By this time, 42% of the world’s p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS omega 2022-12, Vol.7 (50), p.47357-47371
Hauptverfasser: Pushpa, Sreejith Remanan, Sukumaran, Rajeev Kumar, Savithri, Sivaraman
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 47371
container_issue 50
container_start_page 47357
container_title ACS omega
container_volume 7
creator Pushpa, Sreejith Remanan
Sukumaran, Rajeev Kumar
Savithri, Sivaraman
description The World Health Organization (WHO) declared the Omicron variant (B.1.1.529) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for the Coronavirus disease 2019 (COVID-19) pandemic, as a variant of concern on 26 November 2021. By this time, 42% of the world’s population had received at least one dose of the vaccine against COVID-19. As on 1 October 2022, only 68% of the world population got the first dose of the vaccine. Although the vaccination is incredibly protective against severe complications of the disease and death, the highly contagious Omicron variant, compared to the Delta variant (B.1.617.2), has led the whole world into more chaotic situations. Furthermore, the virus has a high mutation rate, and hence, the possibility of a new variant of concern in the future cannot be ruled out. To face such a challenging situation, paramount importance should be given to rapid diagnosis and isolation of the infected patient. Current diagnosis methods, including reverse transcription-polymerase chain reaction and rapid antigen tests, face significant burdens during a COVID-19 wave. However, studies reported ultrarapid, reagent-free, cost-efficient, and non-destructive diagnosis methods based on chemometrics for COVID-19 and COVID-19 severity diagnosis. These studies used a smaller sample cohort to construct the diagnosis model and failed to discuss the robustness of the model. The current study systematically evaluated the robustness of the diagnosis models trained using smaller (real and augmented spectra) and larger (augmented spectra) datasets. The Monte Carlo cross-validation and permutation test results suggest that diagnosis using models trained by larger datasets was accurate and statistically significant (Q 2 > 99% and AUROC = 100%).
doi_str_mv 10.1021/acsomega.2c06786
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9773962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2758353694</sourcerecordid><originalsourceid>FETCH-LOGICAL-a363t-a485cd20013df4c5b4fdfa6b11725cf7601b1775744338fa059abab6bfeba1f83</originalsourceid><addsrcrecordid>eNp1kM1Lw0AQxRdRbKm9e5IcPZi6H8luchFqa7VQqNTW6zKb7MaUJFuzjeB_b6Qf1IOnGZj33jx-CF0TPCCYkntInC11BgOaYC4ifoa6NBDYJyxg5yd7B_WdW2OMCY9oRPkl6jAeCkwi0UWjhVWN21baOc8ab7KcLvxHcDr1VsW2hho2eeqN5u_TsU9ib5xDVlmXO2_l8irzXmdv_nh4hS4MFE7397OHVpOn5ejFn82fp6PhzAfG2daHIAqTlLY9WGqCJFSBSQ1wRYigYWIEx0QRIUIRBIxFBnAYgwLFldEKiIlYDz3scjeNKnWa6KptWMhNnZdQf0sLufx7qfIPmdkvGQvBYk7bgNt9QG0_G-22ssxdoosCKm0bJ6kIIxYyHgetFO-kSW2dq7U5viFY_uKXB_xyj7-13JzWOxoOsFvB3U7QWuXaNnXV0vo_7we8OJBB</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2758353694</pqid></control><display><type>article</type><title>Robustness of FTIR-Based Ultrarapid COVID-19 Diagnosis Using PLS-DA</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Chemical Society (ACS) Open Access</source><source>PubMed Central</source><creator>Pushpa, Sreejith Remanan ; Sukumaran, Rajeev Kumar ; Savithri, Sivaraman</creator><creatorcontrib>Pushpa, Sreejith Remanan ; Sukumaran, Rajeev Kumar ; Savithri, Sivaraman</creatorcontrib><description>The World Health Organization (WHO) declared the Omicron variant (B.1.1.529) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for the Coronavirus disease 2019 (COVID-19) pandemic, as a variant of concern on 26 November 2021. By this time, 42% of the world’s population had received at least one dose of the vaccine against COVID-19. As on 1 October 2022, only 68% of the world population got the first dose of the vaccine. Although the vaccination is incredibly protective against severe complications of the disease and death, the highly contagious Omicron variant, compared to the Delta variant (B.1.617.2), has led the whole world into more chaotic situations. Furthermore, the virus has a high mutation rate, and hence, the possibility of a new variant of concern in the future cannot be ruled out. To face such a challenging situation, paramount importance should be given to rapid diagnosis and isolation of the infected patient. Current diagnosis methods, including reverse transcription-polymerase chain reaction and rapid antigen tests, face significant burdens during a COVID-19 wave. However, studies reported ultrarapid, reagent-free, cost-efficient, and non-destructive diagnosis methods based on chemometrics for COVID-19 and COVID-19 severity diagnosis. These studies used a smaller sample cohort to construct the diagnosis model and failed to discuss the robustness of the model. The current study systematically evaluated the robustness of the diagnosis models trained using smaller (real and augmented spectra) and larger (augmented spectra) datasets. The Monte Carlo cross-validation and permutation test results suggest that diagnosis using models trained by larger datasets was accurate and statistically significant (Q 2 &gt; 99% and AUROC = 100%).</description><identifier>ISSN: 2470-1343</identifier><identifier>EISSN: 2470-1343</identifier><identifier>DOI: 10.1021/acsomega.2c06786</identifier><identifier>PMID: 36570187</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><ispartof>ACS omega, 2022-12, Vol.7 (50), p.47357-47371</ispartof><rights>2022 The Authors. Published by American Chemical Society</rights><rights>2022 The Authors. Published by American Chemical Society.</rights><rights>2022 The Authors. Published by American Chemical Society 2022 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a363t-a485cd20013df4c5b4fdfa6b11725cf7601b1775744338fa059abab6bfeba1f83</citedby><cites>FETCH-LOGICAL-a363t-a485cd20013df4c5b4fdfa6b11725cf7601b1775744338fa059abab6bfeba1f83</cites><orcidid>0000-0002-5389-2394 ; 0000-0002-1315-3650 ; 0000-0003-2220-0583</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsomega.2c06786$$EPDF$$P50$$Gacs$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsomega.2c06786$$EHTML$$P50$$Gacs$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27080,27924,27925,53791,53793,56762,56812</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36570187$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pushpa, Sreejith Remanan</creatorcontrib><creatorcontrib>Sukumaran, Rajeev Kumar</creatorcontrib><creatorcontrib>Savithri, Sivaraman</creatorcontrib><title>Robustness of FTIR-Based Ultrarapid COVID-19 Diagnosis Using PLS-DA</title><title>ACS omega</title><addtitle>ACS Omega</addtitle><description>The World Health Organization (WHO) declared the Omicron variant (B.1.1.529) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for the Coronavirus disease 2019 (COVID-19) pandemic, as a variant of concern on 26 November 2021. By this time, 42% of the world’s population had received at least one dose of the vaccine against COVID-19. As on 1 October 2022, only 68% of the world population got the first dose of the vaccine. Although the vaccination is incredibly protective against severe complications of the disease and death, the highly contagious Omicron variant, compared to the Delta variant (B.1.617.2), has led the whole world into more chaotic situations. Furthermore, the virus has a high mutation rate, and hence, the possibility of a new variant of concern in the future cannot be ruled out. To face such a challenging situation, paramount importance should be given to rapid diagnosis and isolation of the infected patient. Current diagnosis methods, including reverse transcription-polymerase chain reaction and rapid antigen tests, face significant burdens during a COVID-19 wave. However, studies reported ultrarapid, reagent-free, cost-efficient, and non-destructive diagnosis methods based on chemometrics for COVID-19 and COVID-19 severity diagnosis. These studies used a smaller sample cohort to construct the diagnosis model and failed to discuss the robustness of the model. The current study systematically evaluated the robustness of the diagnosis models trained using smaller (real and augmented spectra) and larger (augmented spectra) datasets. The Monte Carlo cross-validation and permutation test results suggest that diagnosis using models trained by larger datasets was accurate and statistically significant (Q 2 &gt; 99% and AUROC = 100%).</description><issn>2470-1343</issn><issn>2470-1343</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>N~.</sourceid><recordid>eNp1kM1Lw0AQxRdRbKm9e5IcPZi6H8luchFqa7VQqNTW6zKb7MaUJFuzjeB_b6Qf1IOnGZj33jx-CF0TPCCYkntInC11BgOaYC4ifoa6NBDYJyxg5yd7B_WdW2OMCY9oRPkl6jAeCkwi0UWjhVWN21baOc8ab7KcLvxHcDr1VsW2hho2eeqN5u_TsU9ib5xDVlmXO2_l8irzXmdv_nh4hS4MFE7397OHVpOn5ejFn82fp6PhzAfG2daHIAqTlLY9WGqCJFSBSQ1wRYigYWIEx0QRIUIRBIxFBnAYgwLFldEKiIlYDz3scjeNKnWa6KptWMhNnZdQf0sLufx7qfIPmdkvGQvBYk7bgNt9QG0_G-22ssxdoosCKm0bJ6kIIxYyHgetFO-kSW2dq7U5viFY_uKXB_xyj7-13JzWOxoOsFvB3U7QWuXaNnXV0vo_7we8OJBB</recordid><startdate>20221220</startdate><enddate>20221220</enddate><creator>Pushpa, Sreejith Remanan</creator><creator>Sukumaran, Rajeev Kumar</creator><creator>Savithri, Sivaraman</creator><general>American Chemical Society</general><scope>N~.</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5389-2394</orcidid><orcidid>https://orcid.org/0000-0002-1315-3650</orcidid><orcidid>https://orcid.org/0000-0003-2220-0583</orcidid></search><sort><creationdate>20221220</creationdate><title>Robustness of FTIR-Based Ultrarapid COVID-19 Diagnosis Using PLS-DA</title><author>Pushpa, Sreejith Remanan ; Sukumaran, Rajeev Kumar ; Savithri, Sivaraman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a363t-a485cd20013df4c5b4fdfa6b11725cf7601b1775744338fa059abab6bfeba1f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pushpa, Sreejith Remanan</creatorcontrib><creatorcontrib>Sukumaran, Rajeev Kumar</creatorcontrib><creatorcontrib>Savithri, Sivaraman</creatorcontrib><collection>American Chemical Society (ACS) Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ACS omega</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pushpa, Sreejith Remanan</au><au>Sukumaran, Rajeev Kumar</au><au>Savithri, Sivaraman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Robustness of FTIR-Based Ultrarapid COVID-19 Diagnosis Using PLS-DA</atitle><jtitle>ACS omega</jtitle><addtitle>ACS Omega</addtitle><date>2022-12-20</date><risdate>2022</risdate><volume>7</volume><issue>50</issue><spage>47357</spage><epage>47371</epage><pages>47357-47371</pages><issn>2470-1343</issn><eissn>2470-1343</eissn><abstract>The World Health Organization (WHO) declared the Omicron variant (B.1.1.529) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for the Coronavirus disease 2019 (COVID-19) pandemic, as a variant of concern on 26 November 2021. By this time, 42% of the world’s population had received at least one dose of the vaccine against COVID-19. As on 1 October 2022, only 68% of the world population got the first dose of the vaccine. Although the vaccination is incredibly protective against severe complications of the disease and death, the highly contagious Omicron variant, compared to the Delta variant (B.1.617.2), has led the whole world into more chaotic situations. Furthermore, the virus has a high mutation rate, and hence, the possibility of a new variant of concern in the future cannot be ruled out. To face such a challenging situation, paramount importance should be given to rapid diagnosis and isolation of the infected patient. Current diagnosis methods, including reverse transcription-polymerase chain reaction and rapid antigen tests, face significant burdens during a COVID-19 wave. However, studies reported ultrarapid, reagent-free, cost-efficient, and non-destructive diagnosis methods based on chemometrics for COVID-19 and COVID-19 severity diagnosis. These studies used a smaller sample cohort to construct the diagnosis model and failed to discuss the robustness of the model. The current study systematically evaluated the robustness of the diagnosis models trained using smaller (real and augmented spectra) and larger (augmented spectra) datasets. The Monte Carlo cross-validation and permutation test results suggest that diagnosis using models trained by larger datasets was accurate and statistically significant (Q 2 &gt; 99% and AUROC = 100%).</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>36570187</pmid><doi>10.1021/acsomega.2c06786</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-5389-2394</orcidid><orcidid>https://orcid.org/0000-0002-1315-3650</orcidid><orcidid>https://orcid.org/0000-0003-2220-0583</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2470-1343
ispartof ACS omega, 2022-12, Vol.7 (50), p.47357-47371
issn 2470-1343
2470-1343
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9773962
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Chemical Society (ACS) Open Access; PubMed Central
title Robustness of FTIR-Based Ultrarapid COVID-19 Diagnosis Using PLS-DA
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T08%3A31%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Robustness%20of%20FTIR-Based%20Ultrarapid%20COVID-19%20Diagnosis%20Using%20PLS-DA&rft.jtitle=ACS%20omega&rft.au=Pushpa,%20Sreejith%20Remanan&rft.date=2022-12-20&rft.volume=7&rft.issue=50&rft.spage=47357&rft.epage=47371&rft.pages=47357-47371&rft.issn=2470-1343&rft.eissn=2470-1343&rft_id=info:doi/10.1021/acsomega.2c06786&rft_dat=%3Cproquest_pubme%3E2758353694%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2758353694&rft_id=info:pmid/36570187&rfr_iscdi=true